No Data
No Data
LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Lanzhou Foci Pharmaceutical (002644.SZ) will distribute a cash dividend of 0.3 yuan per share for 10 consecutive times in 2023. The record date is June 24.
Lanzhou Foci Pharmaceutical (002644.SZ) announced on June 17 that the company's 2023 annual equity distribution plan is based on the existing total share capital of 510,657,000 shares, and will distribute 0.300000 yuan in cash (including tax) to all shareholders for every 10 shares. The equity distribution record date is June 24, 2024, and the ex-rights and ex-dividend date is June 25, 2024.
Lanzhou Foci Pharmaceutical Chairman Resigns
Foci Pharmaceutical (002644.SZ): Net profit for 2023 fell 38.16% to 67.1897 million yuan, and plans to distribute 10 to 0.3 yuan
On April 9, Ge Longhui Pharmaceutical (002644.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1,163 billion yuan, an increase of 11.58%; net profit attributable to shareholders of listed companies was 67.1897 million yuan, a year-on-year decrease of 38.16%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 509.378 million yuan, a year-on-year decrease of 7.57%; basic income per share was 0.1316 yuan; it plans to distribute cash dividends of 0.3 yuan (tax included) for every 10 shares to all shareholders.
While Shareholders of LanZhou Foci PharmaceuticalLtd (SZSE:002644) Are in the Red Over the Last Year, Underlying Earnings Have Actually Grown
Foci Pharmaceutical (002644.SZ): Since March 11, the factory price of its main proprietary Chinese medicine products has been adjusted, with an average price increase of 9%
On March 11, Ge Longhui Pharmaceutical (002644.SZ) announced that due to reasons such as rising raw materials and production costs, the factory price of the main proprietary Chinese medicine products will be adjusted from March 11, 2024, after a study decision by Lanzhou Foci Pharmaceutical Co., Ltd., with an average price increase of 9%.
No Data